Seres Therapeutics (MCRB) Announces SER-287 Phase 1b Microbiome Analyses that Provide Mechanistic Support for Clinical Efficacy in Ulcerative Colitis

January 4, 2018 7:04 AM

Seres Therapeutics, Inc., (NASDAQ: MCRB) today announced initial microbiome results from its Phase 1b study of SER-287, a microbiome therapeutic ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found